The impact of obesity on clinical, metabolic and hormonal features in patients with polycystic ovary syndrome

Year 2014, , 567 - 571, 01.12.2014

Serap Baydur Şahin Fatih Sümer Hacer Sezgin Teslime Ayaz Osman Zikrullah Şahin Kadir İlkkılıç Emine Uslu Gür Ekrem Algün

https://doi.org/10.5799/ahinjs.01.2014.04.0459

Abstract

Objectives: Our aim was to compare the clinical, hormonal and metabolic features between overweight and obese patients with PCOS and normal weight women with polycystic ovary syndrome (PCOS). Methods: 119 patients with PCOS (15-39 years) were included in the study. We evaluated anthropometric, hormonal and metabolic parameters in all patients. Results: Ferriman- Gallwey hirsutism score was similar in overweight or obese patients with PCOS (n=78) and normal weight patients with PCOS (n=41) (p=0.373). While 71.8% of the obese group had irregular menses, this ratio was 60.9% in normal weight group (p=0.160). HOMA-IR values were higher in the obese group (1.7±0.7 vs 3.3±1.7, p

Keywords

Polycystic ovary syndrome; obesity; hirsutism; menstruel regularity; HOMA-IR

Polikistik over sendromlu hastalarda obezitenin klinik, metabolik ve hormonal özellikler üzerine etkisi

Abstract

Amaç: Bu çalışmanın amacı fazla kilolu ve obez polikistik over sendromu (PKOS)\'lu hastalar ile normal kilolu PKOS\'lu kadınları klinik, hormonal ve metabolik özellikler açısından karşılaştırmaktı. Yöntemler: Çalışmaya yaşları 15-39 arasında değişen 119 PKOS\'lu hasta dahil edildi. Tüm hastalarda antropometrik, metabolik ve hormonal ölçümler yapıldı. Bulgular: Fazla kilolu ve obez PKOS\'lu hastalarla (n=78) normal kilolu hastalar (n=41) arasında Ferriman- Gallwey hirsutizm skoru açısından bir fark saptanmadı (p=0,373). Obez grubun %71,8\'inde menstruel düzensizlik görülürken, normal kilolu grupta bu oran %60,9 idi (p=0,160). HOMA-IR değerleri obez grupta anlamlı derecede daha yüksekti (1,7±0,7\'ye karşın 3,3±1,7, p

Keywords

Polikistik over sendromu, obezite, hirsutizm, menstruel düzen, HOMA-IR

References

• Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745-2749.
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consen- sus Workshop Group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19– 25.
• Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril 2002;77:1095-1105.
• Wild RA. Long-term health consequences of PCOS. Hum Reprod Update 2002;8:231-241.
• Legro RS. Polycystic ovary syndrome and cardiovas- cular disease: a premature association? Endocr Rev 2003;24:302-312.
• Horejsi R, Möller R, Rackl S, et al. Android subcuta- neous adipose tissue topography in lean and obese women suffering from PCOS: comparison with type 2 diabetic women. Am J Phys Anthropol 2004;124:275- 281
• Kirchengast S, Huber J. Body composition characteris- tics and body fat distribution in lean women with poly- cystic ovary syndrome. Hum Reprod 2001;16:1255- 1260.
• Legro RS, Arslanian SA, Ehrmann DA, et al: Endo- crine Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical prac- tice guideline. J Clin Endocrinol Metab 2013;98:4565- 4592.
• Diamanti-Kandarakis E. Role of obesity and adipos- ity in polycystic ovary syndrome. Int J Obes (Lond) 2007;31:8-13.
• Pasquali R, Casimirri F, Cantobelli S, et al. Insulin and androgen relationships with abdominal body fat distri- bution in women with and without hyperandrogenism. Horm Res 1993;39:179-187.
• Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165-1174.
• Ehrmann DA, Liljenquist DR, Kasza K, et al; PCOS/ Troglitazone Study Group. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:48- 53.
• Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a system- atic review and meta-analysis. Hum Reprod Update 2010;16:347-363.
• Pasquali R, Gambineri A, Pagotto U. The impact of obesity on reproduction in women with polycystic ova- ry syndrome. BJOG 2006;113:1148-1159.
• Ferriman D, Gallwey JD: Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21: 1440–1447.
• Matthews DR, Hosker JP, Rudenski AS, et al: Homeo- stasis model assessment: insulin resistance and beta- cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412– 419.
• Gokcel A, Ozsahin AK, Sezgin N, et al. High preva- lence of diabetes in Adana, a southern province of Turkey. Diabet Care 2003;26:3031-3034.
• Baldani DP, Skrgatić L, Goldstajn MS, et al. Clinical, hormonal and metabolic characteristics of polycystic ovary syndromeamong obese and nonobese women in the Croatian population. Coll Antropol 2013;37:465- 470.
• Siddiqui IA, Tamimi W, Tamim H, et al. A study on clini- cal and sonographic features in obese and nonobese patients with polycystic ovary syndrome. Arch Gyne- col Obstet 2010;281:467-471.
• Liou TH, Yang JH, Hsieh CH, et al. Clinical and bio- chemical presentations of polycystic ovary syndrome among obese and nonobese women. Fertil Steril 2009;92:1960-1965.
• Zhang HY1, Guo CX, Zhu FF, et al. Clinical char- acteristics, metabolic features, and phenotype of Chinese women with polycystic ovary syndrome: A large-scale case-control study. Arch Gynecol Obstet 2013;287:525-531.
• Tamimi W, Siddiqui IA, Tamim H, et al. Effect of body mass index on clinical manifestations in patients with polycystic ovary syndrome. Int J Gynaecol Obstet 2009;107:54-57.
• Yildiz BO, Knochenhauer ES, Azziz R. Impact of obe- sity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2008;93:162-168.
• Gambineri A, Pelusi C, Vicennati V, et al. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord 2002;26:883-896.